title: Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
abstract: OBJECTIVE
  Azathioprine is effective for Crohn's disease but acts slowly. A loading dose may decrease the time to response.
  
  
  METHODS
  A placebo-controlled study was conducted in patients with active Crohn's disease despite prednisone treatment. Patients were randomized to a 36-hour infusion of azathioprine, 40 mg/kg (51 patients), or placebo (45 patients) followed by oral azathioprine, 2 mg/kg, for 16 weeks. Prednisone was tapered over 5 weeks. The primary outcome measure was complete remission at week 8, defined by discontinuation of prednisone and a Crohn's Disease Activity Index of </=150 points. Erythrocyte concentrations of the azathioprine active metabolite, 6-thioguanine nucleotide, were measured.
  
  
  RESULTS
  At week 8, 13 patients (25%) were in complete remission in the azathioprine-loaded group compared with 11 patients (24%) in the placebo group. The frequency of complete remission did not increase after 8 weeks in either group. Both groups achieved steady state of 6-thioguanine nucleotide by week 2, and no differences were found in mean concentrations between the groups. There were no significant differences in the frequency of adverse events between the groups.
  
  
  CONCLUSIONS
  A loading dose does not decrease the time to response in patients with steroid-treated Crohn's disease beginning azathioprine therapy. Steady state of erythrocyte 6-thioguanine nucleotide and complete response occurred earlier than previously reported.
authors.affiliation: Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: W J
authors.initials: WJ
authors.lastname: Sandborn
authors.forename: W J
authors.initials: WJ
authors.lastname: Tremaine
authors.forename: D C
authors.initials: DC
authors.lastname: Wolf
authors.forename: S R
authors.initials: SR
authors.lastname: Targan
authors.forename: C A
authors.initials: CA
authors.lastname: Sninsky
authors.forename: L R
authors.initials: LR
authors.lastname: Sutherland
authors.forename: S B
authors.initials: SB
authors.lastname: Hanauer
authors.forename: J W
authors.initials: JW
authors.lastname: McDonald
authors.forename: B G
authors.initials: BG
authors.lastname: Feagan
authors.forename: R N
authors.initials: RN
authors.lastname: Fedorak
authors.forename: K L
authors.initials: KL
authors.lastname: Isaacs
authors.forename: M G
authors.initials: MG
authors.lastname: Pike
authors.forename: D C
authors.initials: DC
authors.lastname: Mays
authors.forename: J J
authors.initials: JJ
authors.lastname: Lipsky
authors.forename: S
authors.initials: S
authors.lastname: Gordon
authors.forename: C S
authors.initials: CS
authors.lastname: Kleoudis
authors.forename: R H
authors.initials: RH
authors.lastname: Murdock
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage* / Q000627:therapeutic use; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004912:Erythrocytes; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007958:Leukocyte Count; D008297:Male; D008780:Methyltransferases / Q000097:blood; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D013866:Thioguanine / Q000097:blood
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D013866:Thioguanine; D001379:Azathioprine; D011241:Prednisone